46.45MMarket Cap-640P/E (TTM)
1.420High1.380Low105.84KVolume1.390Open1.440Pre Close149.00KTurnover1.18%Turnover RatioLossP/E (Static)33.42MShares9.21052wk High0.57P/B12.49MFloat Cap0.98052wk Low--Dividend TTM8.98MShs Float17.180Historical High--Div YieldTTM2.78%Amplitude0.980Historical Low1.407Avg Price1Lot Size
Reneo Pharmaceuticals Stock Forum
$Merck & Co(MRK.US)$ to acquire EyeBio
$Biogen(BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US)$
$Novartis AG(NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔
$Biogen(BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US)$
$Harmony Biosciences(HRMY.US)$ acquired Epygenix Tx
What companies will be next? 🤔
NEWS
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Reneo Pharmaceuticals and OnKure announced a merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focusing on advancing OnKure's precision medicines in oncology. The combined company is expected to have $120 million in cash resources at close, funding through 2026. OnKure's lead program, OKI-219, is in a Phase 1 clinical trial for solid tumors.
well..a kind of first green day anyway
No comment yet